Sattva Sukun Lifecare Delays Q2 Results Due to Subsidiary Acquisition

1 min read     Updated on 05 Dec 2025, 12:47 PM
scanx
Reviewed by
Ashish TScanX News Team
Overview

Sattva Sukun Lifecare Limited has postponed filing its financial results for Q2 and H1 ending September 30, 2025, due to the recent acquisition of Pavapuri Export Private Limited. The delay is attributed to the need for preparing consolidated financial statements, aligning accounting policies, and finalizing consolidated accounts. The company has rescheduled its board meeting to November 25, 2025, for approving the financial results. Sattva Sukun Lifecare has informed the BSE Limited that the delay was unintentional and caused by procedural requirements related to the acquisition.

26464638

*this image is generated using AI for illustrative purposes only.

Sattva Sukun Lifecare Limited , formerly known as Mayukh Dealtrade Limited, has reported a delay in filing its financial results for the quarter and half-year ended September 30, 2025. The company attributes this delay to the recent acquisition of a subsidiary, Pavapuri Export Private Limited, during the reporting period.

Reasons for Delay

The company cited several factors contributing to the postponement:

  1. Subsidiary Acquisition: The acquisition of Pavapuri Export Private Limited necessitated the preparation of consolidated financial statements.
  2. Integration Process: The following steps were required for proper integration:
    • Verification and alignment of accounting policies and reporting frameworks
    • Preparation and validation of consolidated accounts
    • Review of financial data and reconciliations
    • Finalization of consolidated financial statements

Timeline of Events

Event Date
Reporting Period End September 30, 2025
Board Meeting (Rescheduled) November 25, 2025
Financial Results Approval November 25, 2025

Company's Statement

In a clarification to the BSE Limited, Sattva Sukun Lifecare emphasized that the delay was unintentional and solely due to procedural and consolidation requirements arising from the new subsidiary acquisition. The company stated that it remains committed to statutory compliance and timely disclosures in accordance with SEBI regulations.

Impact and Compliance

While the delay in filing financial results is a deviation from the standard reporting timeline set by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has taken steps to address the issue:

  1. Provided a detailed explanation to the stock exchange
  2. Submitted the financial results along with the Limited Review Report post-approval

Investors and stakeholders should note that such delays, while not ideal, can occur during significant corporate actions like acquisitions. The company's transparency in explaining the delay and its commitment to regulatory compliance are positive signs for maintaining investor trust.

As the financial data is not readily available, investors are advised to review the complete financial results once they are publicly disclosed to assess the company's performance and the impact of the new subsidiary on its financials.

Historical Stock Returns for Sattva Sukun Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
+3.77%-16.67%-30.38%-48.60%-48.60%-25.68%
Sattva Sukun Lifecare
View in Depthredirect
like19
dislike

Sattva Sukun Lifecare Reports Strong Q2 FY2026 Performance and Completes Rights Issue

2 min read     Updated on 25 Nov 2025, 07:14 PM
scanx
Reviewed by
Ashish TScanX News Team
Overview

Sattva Sukun Lifecare Limited (SSLL) reported net sales of Rs 195.98 lakhs and a profit of Rs 60.40 lakhs for Q2 FY2026. The company successfully completed a rights issue of 19.16 crore equity shares, raising Rs 1,916 lakhs. The funds are allocated for strategic investment in subsidiary PavaPuri Export Private Limited (Rs 1,000 lakhs), business expansion (Rs 287.82 lakhs), working capital (Rs 130.75 lakhs), and other purposes. SSLL's financial position shows growth in assets, revenue, and net profit based on FY 2025 data.

25623881

*this image is generated using AI for illustrative purposes only.

Sattva Sukun Lifecare Limited (SSLL), formerly known as Mayukh Dealtrade Limited, has reported a robust performance for the second quarter of fiscal year 2026, along with the successful completion of a significant rights issue.

Q2 FY2026 Financial Highlights

SSLL reported standalone net sales of Rs 195.98 lakhs for Q2 FY2026, demonstrating the company's continued growth trajectory. The company's profit for the quarter stood at Rs 60.40 lakhs, indicating a solid bottom-line performance.

Rights Issue and Capital Allocation

SSLL completed a rights issue of 19.16 crore equity shares, raising a total of Rs 1,916 lakhs. This capital infusion is expected to provide the company with resources to pursue its expansion plans and strategic investments.

The company has allocated the funds raised from the rights issue as follows:

Purpose Amount (Rs in lakhs)
Strategic investment in subsidiary PavaPuri Export Private Limited 1,000.00
Business expansion plans 287.82
Working capital requirements 130.75
General corporate purposes 99.90
Issue-related expenses 47.40

Strategic Investment and Expansion

A significant portion of the rights issue proceeds, Rs 1,000 lakhs, has been earmarked for strategic investment in SSLL's subsidiary, PavaPuri Export Private Limited. This move suggests that the company is focusing on strengthening its group structure and potentially expanding its export-oriented business.

Additionally, SSLL has allocated Rs 287.82 lakhs towards business expansion plans. While specific details of these plans were not provided, this investment indicates the company's commitment to growth and market expansion.

Financial Position

Based on the latest available financial data as of March 2025:

Metric Value (Rs in crore) YoY Change
Total Assets 26.60 14.66%
Current Assets 14.40 28.57%
Total Equity 23.90 7.66%
Revenue (FY 2025) 5.70 58.33%
Net Profit (FY 2025) 2.50 108.33%

The company's balance sheet shows growth in total assets and current assets, indicating improved liquidity and operational capacity. The increase in revenue and net profit for FY 2025 demonstrates SSLL's strong financial performance.

Conclusion

Sattva Sukun Lifecare Limited's Q2 FY2026 results, coupled with the completion of its rights issue, indicate a company on a growth trajectory. The strategic allocation of funds towards subsidiary investment and business expansion suggests that SSLL is positioning itself for future opportunities in the market.

Investors and stakeholders may be interested in observing how these investments translate into long-term value creation for the company. As always, it's important for investors to conduct their own research and consider their individual financial goals before making investment decisions.

Historical Stock Returns for Sattva Sukun Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
+3.77%-16.67%-30.38%-48.60%-48.60%-25.68%
Sattva Sukun Lifecare
View in Depthredirect
like18
dislike
More News on Sattva Sukun Lifecare
Explore Other Articles
0.55
+0.02
(+3.77%)